News and Press


Nature Magazine: FDA grants first approval for plant-made pharmaceutical; Ventria Bioscience weighs in on significance for PMP industry.

Last week, the FDA gave its first-ever regulatory clearance for a plant-made pharmaceutical (PMP) product. As discussed in today’s article in Nature, this is an important development for the PMP industry not only because it opens a pathway for FDA approval, but also because it signals biotherapeutics developers that they should consider plants as an alternative, lower cost manufacturing system. Ventria Bioscience’s CEO is quoted in the article, and our lead therapeutic candidate VEN100 is shown in a chart showing plant-made pharmaceuticals in the pipeline.

» Read the full article in Nature